AI-Assisted Drug Repurposing Strategies

Abstract

Drug repurposing, the process of identifying new therapeutic uses for existing drugs, is an accelerating field driven by the urgent need for efficient and cost-effective solutions to address unmet clinical needs. Artificial intelligence (AI) has emerged as a transformative tool in this arena, offering advanced computational methods to analyze large-scale biological, chemical, and clinical datasets. This review explores state-of-the-art AI-assisted drug repurposing strategies, discussing their epidemiological impact, mechanistic underpinnings, clinical applications, and future scope. The article synthesizes recent PubMed evidence, clinical guidelines, and expert analysis to guide healthcare professionals in understanding the practical implications and challenges of AI-driven drug repurposing.

Introduction

Drug development is traditionally a lengthy and expensive process, often taking over a decade and costing billions of dollars to bring a new therapy to market. Drug repurposing, also known as drug repositioning, offers a strategic alternative by leveraging approved or investigational drugs for new indications. The advent of AI, including machine learning (ML) and deep learning (DL) technologies, has revolutionized the ability to extract actionable insights from vast biomedical data, accelerating drug repurposing efforts. This review provides a comprehensive overview of AI-assisted drug repurposing strategies, focusing on their clinical relevance, mechanistic rationale, and evidence-based outcomes.

Epidemiology / Disease Burden

Globally, the burden of chronic diseases, rare disorders, and emerging infectious diseases continues to rise, highlighting the demand for rapid deployment of effective treatments. Drug repurposing can address these challenges by circumventing early-phase safety trials, reducing costs, and shortening development timelines. AI-driven repurposing is particularly relevant in the context of pandemics, such as COVID-19, where time-sensitive therapeutic interventions are critical. Recent studies have demonstrated that AI-assisted repurposing can significantly increase the rate at which viable drug candidates are identified for high-burden conditions, such as oncology, neurodegeneration, and infectious diseases.

Pathophysiology

Understanding disease pathophysiology is fundamental to effective drug repurposing. AI algorithms can interrogate multi-omics data, including genomics, transcriptomics, proteomics, and metabolomics, to elucidate disease mechanisms and identify molecular targets amenable to repurposed drugs. Network-based approaches, such as network pharmacology and systems biology models, are frequently employed to map complex interactions between drugs, targets, and disease pathways. By integrating heterogeneous data sources, AI enables the identification of shared molecular mechanisms across different diseases, thus highlighting potential cross-indications for existing drugs.

Risk Factors

Risk factor profiling is essential in evaluating the suitability of repurposed drugs for specific patient populations. AI models can analyze electronic health records (EHRs), real-world evidence, and patient registries to stratify patients based on comorbidities, genetic predispositions, and biomarker profiles. This stratification enhances the precision of repurposing efforts, allowing for personalized therapeutic recommendations and risk mitigation strategies. For example, AI-assisted pharmacogenomics has been instrumental in identifying patient subgroups most likely to benefit from certain repurposed medications, thereby optimizing clinical outcomes and minimizing adverse effects.

Clinical Features

The clinical manifestations of diseases targeted for drug repurposing are often heterogeneous, necessitating comprehensive phenotypic characterization. AI-driven natural language processing (NLP) and pattern recognition techniques can extract phenotypic data from unstructured clinical notes, imaging reports, and pathology records. This enables the identification of novel disease subtypes, atypical presentations, and patient cohorts suitable for repurposed therapies. Furthermore, AI can predict potential off-target effects and drug-drug interactions, thereby informing clinical decision-making and patient safety assessments.

Diagnosis

Accurate and timely diagnosis is integral to successful drug repurposing. AI algorithms enhance diagnostic precision by integrating clinical, laboratory, and imaging data, facilitating the early identification of diseases amenable to repurposed treatments. Machine learning models can uncover diagnostic biomarkers and predict disease progression, enabling clinicians to select the most appropriate candidates for repurposed drug interventions. For instance, AI-assisted imaging analysis has been used to identify early signs of neurodegenerative diseases, informing the selection of repurposed neuroprotective agents.

Treatment & Management

AI-assisted drug repurposing has led to the identification of several promising treatment options across diverse therapeutic areas. Notable examples include the use of metformin for cancer prevention, statins for neurodegenerative diseases, and antivirals for emergent viral infections. AI-driven approaches, such as virtual screening, molecular docking, and predictive modeling, enable the systematic evaluation of drug-target interactions and therapeutic efficacy. These methods support the rational selection of drug candidates and inform dosage optimization, combination therapies, and monitoring protocols. Clinicians can leverage AI-generated evidence to inform shared decision-making and personalized treatment plans.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advancements in AI-assisted drug repurposing, fueled by the proliferation of open-access data repositories, improved computational power, and the development of sophisticated AI models. Deep learning frameworks, such as convolutional neural networks (CNNs) and generative adversarial networks (GANs), have been applied to predict drug efficacy, toxicity, and repurposing potential with high accuracy. Knowledge graphs, integrating multi-dimensional data, facilitate the discovery of novel drug-disease associations. Emerging therapies identified through AI-assisted repurposing include anti-inflammatory agents for COVID-19, kinase inhibitors for autoimmune diseases, and antimalarials for oncology indications. Ongoing clinical trials are evaluating the real-world effectiveness and safety of these repurposed therapies.

Guideline Recommendations

Professional societies and regulatory agencies are increasingly recognizing the role of AI in drug repurposing. Recent guidelines emphasize the importance of rigorous validation, real-world evidence generation, and multidisciplinary collaboration in the translation of AI-assisted discoveries into clinical practice. It is recommended that clinicians critically appraise AI-generated evidence, prioritize patient safety, and engage in shared decision-making. Integration of AI-driven insights into clinical guidelines remains an evolving area, requiring ongoing research, transparent reporting, and harmonization of regulatory frameworks to maximize the clinical impact of repurposed drugs.

Conclusion

AI-assisted drug repurposing represents a paradigm shift in therapeutic innovation, offering the potential for rapid, cost-effective, and evidence-based identification of new indications for existing drugs. By harnessing the power of advanced computational methods, clinicians and researchers can address unmet medical needs, improve patient outcomes, and accelerate the translation of scientific discoveries into practice. Continued investment in data infrastructure, algorithm development, and interdisciplinary collaboration is essential to fully realize the promise of AI-driven drug repurposing in modern medicine.